|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8 GBX | 0.00% |
|
0.00% | -5.88% |
| 25/04 | N4 Pharma strikes partnership deal for intracellular delivery | AN |
| 23/04 | N4 Pharma loss widens but "great optimism" remains | AN |
N4 Pharma Plc reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was GBP 0.001953 million. Net loss was GBP 1.27 million compared to GBP 1.03 million a year ago.
Basic loss per share from continuing operations was GBP 0.0052 compared to GBP 0.0055 a year ago. Diluted loss per share from continuing operations was GBP 0.0052 compared to GBP 0.0055 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -5.88% | 2.69M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
N4 PHARMA PLC 